Adverse events reported during weekly isoniazid-rifapentine (3HP) tuberculosis preventive treatment among people living with HIV in Uganda.

Jillian L Kadota Allan MusinguziHélène E AschmannLydia AkelloFred WelisheJane NakimuliChristopher Allen Berger Noah Kiwanuka Patrick Peter John Phillips Achilles Katamba David W Dowdy Adithya Cattamanchi Fred Collins Semitala

Published in: medRxiv : the preprint server for health sciences (2024)

In a routine setting, 3HP was safe with 16% of PLHIV reporting AEs and only 3% requiring temporary or permanent treatment interruption. These findings support 3HP expansion in routine HIV/AIDS care settings for TB prevention.

Keyphrases

hiv aids
mycobacterium tuberculosis
clinical practice
emergency department
palliative care
adverse drug
hepatitis c virus
pulmonary tuberculosis
human immunodeficiency virus
combination therapy
chronic pain
replacement therapy
health insurance